✦ LIBER ✦

Biological and clinical results of a neuroimmunotherapy with interleukin-2 and the pineal hormone melatonin as a first line treatment in advanced non-small cell lung cancer

✍ Scribed by Lissoni, P; Tisi, E; Barni, S; Ardizzoia, A; Rovelli, F; Rescaldani, R; Ballabio, D; Benenti, C; Angeli, M; Tancini, G

Book ID: 109836746
Publisher: Nature Publishing Group
Year: 1992
Tongue: English
Weight: 742 KB
Volume: 66
Category: Article
ISSN: 0007-0920
DOI: 10.1038/bjc.1992.234

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Activity and safety of erlotinib as seco

Activity and safety of erlotinib as second- and third-line treatment in elderly patients with advanced non-small cell lung cancer: a phase II trial

✍ David Rossi; Donatella Dennetta; Marcello Ugolini; Vincenzo Catalano; Paolo Ales 📂 Article 📅 2010 🏛 Springer-Verlag 🌐 English ⚖ 129 KB

A phase I/randomized phase II, non-compa

A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC)

✍ Roger B. Cohen; Corey J. Langer; George Rajan Simon; Peter David Eisenberg; John 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 387 KB

Phase II study of pemetrexed disodium, a

Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma : A study of the national cancer institute of Canada clinical trials group

✍ Frances A. Shepherd; Janet Dancey; Andrew Arnold; Alan Neville; James Rusthoven; 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 3 views

## Background: Pemetrexed disodium (alimta [eli lilly and company, indianapolis, in], ly231514, multitargeted antifolate) is a new multitargeted antifolate agent that inhibits multiple enzymes in the folate pathway. phase ii trials showed single-agent response rates of 16% and 23% in untreated pati